GaPSMA - patents, research & applications

240Patents

1,122Research papers

167Patents - last 3 years

217Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Progenics Pharmaceuticals Inc	19
2	Cornell University	16
3	Deutsches Krebsforschungszentrum DKFZ	10
4	Novartis AG	9
5	Johns Hopkins University	8

6	Albert Ludwigs Universitaet Freiburg	7
7	University of California San Diego UCSD	7
8	Curium US LLC	6
9	Amgen Inc	5
10	The University of Texas System	4

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61K`	Medicinal preparations	194
2	`A61P`	Therapeutic activity (drug indications)	138
3	`C07D`	Heterocyclic compounds	66
4	`C07B`	General methods of organic chemistry	61
5	`C07K`	Peptides	44

6	`G06T`		40
7	`A61B`		33
8	`C07F`	Organometallic compounds	31
9	`G16H`	Digital health, healthcare informatics	29
10	`C07C`	Acyclic and carbocyclic compounds	26

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#	Research topic	Papers
1	Prostate Cancer Treatment and Research	7
2	Glioma Diagnosis and Treatment	1
3	Renal cell carcinoma treatment	1
4	Sarcoidosis and Beryllium Toxicity Research	1
5	Thyroid Cancer Diagnosis and Treatment	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Matthias Eiber	Technical University of Munich	41
2	Ali Afshar‐Oromieh	University Hospital Heidelberg	29
3	Jérémie Calais	University of California, Los Angeles	26
4	Wolfgang P. Fendler	Essen University Hospital	23
5	Benedikt Kranzbühler	University of Zurich	10

6	Boris Hadaschik	Essen University Hospital	19
7	Louise Emmett	St Vincent's Hospital Sydney	18
8	Francesco Ceci	University of Bologna	16
9	Uwe Haberkorn	Heidelberg University	15
10	Andrea Farolfi	University of Bologna	14

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study	2021	426	Prostate Cancer Diagnosis and Treatment
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection	2021	341	Prostate Cancer Diagnosis and Treatment
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings	2020	287	Medical Imaging Techniques and Applications
Metaanalysis of ⁶⁸Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology	2018	254	Prostate Cancer Treatment and Research
Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy	2019	238	Prostate Cancer Treatment and Research

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of GaPSMA?

GaPSMA has the molecular formula C44H59GaN6O17 with a molecular weight of 1013.704. The compound is a gallium-68 complex with a prostate-specific membrane antigen targeting ligand, also known by the synonym Prostamedix.

Which organizations hold the most patents related to GaPSMA?

Progenics Pharmaceuticals Inc leads with 19 patents, followed by Cornell University with 16 patents and Deutsches Krebsforschungszentrum DKFZ with 10 patents. Novartis AG holds 9 patents, and Johns Hopkins University holds 8 patents in this area.

Who are the most prolific researchers publishing on GaPSMA?

Matthias Eiber from Technical University of Munich is the leading author with 37 papers, followed by Ali Afshar‐Oromieh from University Hospital Heidelberg with 29 papers. Jérémie Calais from University of California, Los Angeles has published 24 papers, and Wolfgang P. Fendler from Essen University Hospital has 21 papers on this compound.

What patent classifications are most common for GaPSMA-related intellectual property?

The dominant patent classifications are A61K (194 patents) covering pharmaceutical preparations, followed by A61P (138 patents) for therapeutic applications. Chemical synthesis classifications C07D (66 patents) and C07B (61 patents) are also frequently represented, along with biomedical imaging classification G06T (40 patents).

How has research activity on GaPSMA evolved in recent years?

Patent activity has shown steady growth, with 48 patents in 2022, 53 in 2023, and 55 in 2024, reaching 72 in 2025. Academic publication peaked in 2019 with 160 papers, then declined to 75 papers in 2023 before recovering to 107 papers in 2024. The most highly cited paper on this compound has 418 citations.